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ABSTRACT 
THE POTENTIAL ROLE OF AIRAP/AIRAPL IN AMELIORATING THE TOXICITY 
RELATED TO AMYLOID-BETA (Aβ) IN MAMMALIAN NEURONAL CELLS 
 
by 
Advaita Chakraborty 
 
The University of Wisconsin-Milwaukee, 2017 
Under the Supervision of Professor Wail Hassan 
 
 
Alzheimer’s disease is an irreversible and progressive brain disorder that affects memory and 
thinking skills. It is considered to be one of the most important causes of dementia in older 
adults. The disease is accompanied by accumulation of amyloid beta (Aβ) plaques in the brains 
of patients and presence of neurofibrillary tangles (NFTs) in the nerve tissue. The tangles are 
formed by a protein known as protein-tau (p-tau). Aβ plaques are responsible for 
neurodegeneration, cognitive decline, and loss of memory in patients affected with Alzheimer’s 
disease. It is estimated that Alzheimer’s disease ranks third, just behind heart disease and cancer, 
as a cause of death for the elderly in the United States. AIRAP and AIRAPL are ubiquitin-
binding proteins that are thought to enhance the function of the proteasome by clearing out the 
misfolded proteins from the brain. Previous studies have shown that AIP-1 (a homologue of 
AIRAP and AIRAPL) was overexpressed in a Caenorhabditis elegans disease model which in 
turn helped to reduce the accumulation of Aβ and thus had a protective effect against Aβ 
toxicity. The purpose of our study is to test whether AIRAP and AIRAPL are protective against 
the toxicity associated with Aβ in mammalian neuronal cells. We are hypothesizing that AIRAP 
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and AIRAPL are protective against Aβ toxicity in HT22 hippocampal cells, which would 
significantly decelerate the progression of Alzheimer’s disease. We have manipulated the 
expression of AIRAP and AIRAPL and studied the effect of overexpression and knockdown on 
Aβ toxicity. Overexpression was achieved by establishing transfected cell lines overexpressing 
AIRAP and AIRAPL with help of a CMV constitutive promoter. On the other hand, knockdown 
of genes was attained using specific DsiRNA. Using Trypan Blue staining, we found that cell 
lines overexpressing AIRAP/AIRAPL could lower Aβ toxicity, thus increasing the number of 
viable cells. Additionally, knocking down AIRAP/AIRAPL expression appeared to worsen the 
condition of cells, as the number of dead cells increased, in response to Aβ treatment. With help 
of real-time PCR, mRNA levels of AIRAP and AIRAPL was measured. It was shown that 
expression of both AIRAP and AIRAPL was enhanced during the initial stages of induction in 
cell line having induced Aβ. However, as the induction time increased, the expression levels 
started to fall off. Further studies are essential to know the exact mechanism behind 
AIRAP/AIRAPL protection against Aβ toxicity.   
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INTRODUCTION 
Alzheimer’s Disease: Global impact, symptoms, and causes 
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly (1). The disease 
affects around 75% of the 35 million people suffering from dementia worldwide. It is estimated 
that by the year 2050, around 115 million people will be affected by AD, since the number is 
increasing at a fast pace every year (2). In developing Countries, it has been reported that 1 out 
of each 10 individuals who are 65 years of age or older and one-third of those who are over 85 
years old, suffer from some form of dementia (2). Mild cognitive impairment (MCI) is a term 
that includes a broad spectrum of cognitive impairment syndromes that precedes AD and 
dementia (3). It often depicts a transitional phase between normal aging and dementia (4). The 
disease leads to cognitive defects that affects memory, judgment, insight, and language functions 
(5). In aging, cognitive decline is a common feature and it is observed that changes in cognition 
represents early signs of neurodegenerative disease, ultimately leading to dementia (4). 
Furthermore, weight loss is common in Alzheimer’s patients and this could be a marker of 
approaching AD in people with MCI (3). A clinical and community-based study showed that 
around 40% patients with AD have sleep disturbances (6).  
AD, similar to all kinds of dementia, is caused by death of brain cells. With time, the total brain 
size shrinks since the tissue has fewer nerve cells and connections (7). Postmortem/autopsy 
reports showed that tiny inclusions known as plaques and neurofibrillary tangles (NFTs) are 
present in the nerve tissue. Plaques are found between the dying cells in the brain. These plaques 
are formed from a protein called beta-amyloid (Aβ) (7). The tangles are found intracellularly in 
the brain neurons either from hyperphosphorylation of protein tau (p-tau) or disintegration of p-
tau, which is a tubulin-associated protein (7). The deposition of Aβ leads to the initial 
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neurodegenerative and neurotoxic cascade and relates strongly with decreased cognitive 
performance in an individual (1). The main underlying causes of neurodegeneration, cognitive 
decline, and memory loss are the presence of Aβ and tau-related neuropathies in the brains of 
patients. Aβ peptides are 39-43 amino acid peptides that are derived from the proteolytic 
hydrolysis of amyloid-β precursor protein (AβPP) in neurons and other cell types. (8). The 
presence of NFTs is accompanied by gliosis, loss of neurons and synapses (9). Aβ and p-tau lead 
to chronic inflammatory response and oxidative damage, resulting in progressive neuronal 
degeneration (10).  It has been shown that there is a decrease in Aβ42 levels in the cerebrospinal 
fluid (CSF) and an increase in CSF p-tau levels that can be a biomarker of pathologic changes in 
the brain that ultimately lead to AD or increases the risk of developing the disease. These 
changes have been associated in patients with MCI who eventually will develop AD later in life 
(11).         
 
Clearance of Aβ and importance of Proteasome 
There are three pathways that help to clear Aβ from the brain. They are: transport across blood-
brain barrier (BBB), degradation in the brain tissue, and bulk flow of cerebrospinal fluid (CSF). 
However, clearance across BBB is considered to be the most efficient for removing Aβ (8). It is 
believed that accumulation of Aβ in AD patients is due to inadequate Aβ elimination, with 
patients showing less than 30% clearance of Aβ from the brain (1). The level of Aβ in the brain 
is determined by its production and clearance. The imbalance occurs between the two processes 
that leads to accumulation of Aβ in the brain (8). It is believed that age-related accumulation of 
damaged proteins result both from increased damage and lower efficiency of degradative 
systems. The proteasome system most often helps in clearing the oxidatively modified proteins 
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and it is the main pathway that removes damaged proteins and it is responsible for maintaining 
the proteostasis especially during stress conditions (12).  
However, proteasome function declines with age in various cell types and organs, and this has 
been shown in various studies. As a result, decline in the activity of proteasome results in 
accumulation of oxidized proteins (12). There are significant implications on various 
neurodegenerative diseases due to the reduction in the activity of proteasome and other 
intracellular proteolytic machineries (12). Ubiquitin-proteasome system, a part of the protein 
quality control system (PQC), helps to degrade misfolded or damaged proteins and removes 
proteins involved in various cellular processes, such as, signal transduction, regulation of cell 
cycle, cell death, and finally regulates gene transcription. This system uses two strategies in 
order to maintain protein homeostasis during protein misfolding (12). Misfolded proteins can be 
refolded back in order to recover the normal conformation. Molecular chaperons, such as heat 
shock proteins (HSPs), play a vital role in protein refolding (12). In other cases, the proteins are 
directed towards the ubiquitin-proteasome system for degradation (12).  
Structurally, the 26S proteasome holocomplex consists of a 20S catalytic core and a 19S 
regulatory cap on either end. The 20S subunit has four stacked rings that form a barrel-shaped 
molecule with a central cavity (13). The α-rings are the outer two non-catalytic rings and the two 
catalytic inner rings are known as β-rings. There are three proteolytic activities that are confined 
to the β-rings, chymotrypsin-like, caspase-like, and trypsin-like. (13).  
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Figure 1: 26S proteasome holocomplex 
 
Growing evidences support that impaired proteostasis result in the increase of 
unfolded/misfolded proteins and formation of protein aggregates, which plays a vital role in the 
pathology of AD (14). In addition, a study demonstrated that Aβ oligomers, but not monomers, 
inhibited the activity of the proteasome in 3xTg-AD mice (pathology of AD is studied in this 
type of mice) when there are high levels of the oligomers present. Also, it was shown that there 
was accumulation of both Aβ and tau proteins when the activity of proteasome was inhibited 
(15). As a result, the proteasome is a vital pathway that links Aβ and tau pathology. Hence, it has 
been postulated that the function of the proteasome needs to be enhanced, so that the Aβ could be 
effectively cleared from the brain (15).  
 
Function of AIRAP/AIRAPL including earlier studies 
Arsenite-inducible RNA-associated protein (AIRAP) and AIRAP-like protein (AIRAPL) are 
ubiquitin-binding proteins that help to enhance the activity of proteasome in response to stress 
(16). It is demonstrated that functional impairment of AIP-1, a homologue of AIRAP and 
AIRAPL leads to acceleration in aging and protein aggregation in Caenorhabditis elegans 
disease model (16). In another study, AIP-1 was shown to be overexpressed in C. elegans in 
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what appeared to be a protective response against Aβ toxicity that led to reducing the 
accumulation of Aβ. Moreover, it was noted that transgenic expression of AIRAPL, but not 
AIRAP expression inhibited the toxicity related to Aβ in the worm model (17).  It is evident 
from this study that AIRAP did not have a protective effect against Aβ toxicity in the worm 
model. But, it is not necessary that it won’t be having any neuroprotective effect in mammals. 
Hence, we want to use both AIRAP and AIRAPL and study the effects they have related to Aβ 
toxicity in the cells.  
 
OVERALL GOAL 
The goal of this study is to test whether AIRAP and AIRAPL are protective against Aβ toxicity 
in mammalian neuronal cells. In order to test whether AIRAP and AIRAPL are protective, we 
will manipulate the expression of the two genes to test the effect of overexpression and 
knockdown on Aβ toxicity.  
 
INNOVATION/ IMPACT 
Drug targets that enhance the expression of AIRAP/AIRAPL that in turn reduce the toxicity 
related to Aβ could be a potential therapeutic drug target used in case of Alzheimer’s patients. 
Hence, if AIRAP/AIRAPL offer protection against Aβ toxicity via enhanced proteasomal 
function in mammalian system, it would be useful in decelerating the progression of AD.  
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HYPOTHESIS AND SPECIFIC AIMS 
The central hypothesis of this study was that AIRAP and AIRAPL genes are protective 
against Aβ toxicity. To examine this hypothesis, I proposed the following specific aims: 
Specific Aim 1: To determine Aβ toxicity in mammalian neuronal cells. The working 
hypothesis of this aim: Aβ increases cell death and lowers the cell viability in the neuronal cells. 
Specific Aim 2: To determine whether AIRAP/AIRAPL genes reduce cell death/ improve 
cell viability. The working hypothesis of this aim: AIRAP/AIRAPL improve cell viability of 
neuronal cells.   
Specific Aim 2.1: To investigate the effect of overexpression of AIRAP/AIRAPL on cell 
viability. The working hypothesis of this aim: Overexpression of AIRAP/AIRAPL reduces cell 
death and increases the viability of cells. Overexpression was achieved by establishing stably 
transfected cell lines overexpressing AIRAP or AIRAPL using a cytomegalovirus (CMV) 
constitutive promoter. 
Specific Aim 2.2: To determine the effect of knock down of AIRAP/AIRAPL on the cell 
viability. The working hypothesis of this aim: Knocking down AIRAP/AIRAPL increases the 
cell death and there was lower number of viable cells present. Knock down was achieved using 
specific dicer-substrate interfering RNA (DsiRNA).         
Specific Aim 3: To ascertain the over-expression of AIRAP/AIRAPL in presence of induced 
Aβ. The working hypothesis of this aim: AIRAP/AIRAPL were found to be overexpressed in 
presence of Aβ in mammalian neuronal cells.  
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MATERIALS AND METHODS 
Construction of Plasmids 
We have constructed various plasmids containing either AIRAP or AIRAPL gene. Plasmids 
pWH017, pWH018, and pWH019 possess different variants of the human Amyloid-β precursor 
protein (APP) gene. Next, we transfected the plasmids into the HT22 neuronal cells and studied 
the effects of the genes when overexpressed/ knocked out in presence of Aβ treatment. 
Moreover, we also designed plasmids without AIRAP and AIRAPL genes (pWH020 and 
pWH021 respectively) that served as controls. Detailed description of the plasmids is provided 
below. 
 pWH013 (9853 bp): This was constructed using plasmid pWH002 (containing 
human CMV promoter and AIRAP gene) and cut with HindIII enzyme (New 
England Biolabs, Ipswich, MA, Cat. No. R3104S). The product of 6557 bp was 
ligated with the PCR products of AcGFP (template: pAcGFP1-Hyg-N1 and 
primers: CL-AcGFP1-F and CL-AcGFP1-R) of 1625 bp and Hygromycin 
(template: pAcGFP1-Hyg-N1 and primers: CL-Hygromycin-F and CL-
Hygromycin-R) of 1725 bp. Cloning was performed using NEBuilder Assembly 
(HiFi DNA Master Mix: New England Biolabs, Ipswich, MA, Cat. No. M5520S; 
NEBuilder Positive Control: New England Biolabs, Ipswich, MA, Cat. No. 
N2611A). Transformation was done using high efficiency competent 5α E. coli 
cells (New England Biolabs, Ipswich, MA, Cat. No. C2987H; SOC Medium: New 
England Biolabs, Ipswich, MA, Cat. No. B9020S; pUC 19 Control DNA: New 
England Biolabs, Ipswich, MA, N3041A).   
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Figure 2. Plasmid pWH013 
 
 pWH014 (10189 bp): Plasmid pWH001 (presence of human CMV promoter and 
AIRAPL gene) was cut with HindIII enzyme (New England Biolabs, Ipswich, 
MA, Cat. No. R3104S) and the product of 6557 bp was ligated with the PCR 
products of AcGFP (1625 bp) and Hygromycin (1725 bp). This was done with 
help of NEBuilder Assembly (HiFi DNA Master Mix: New England Biolabs, 
Ipswich, MA, Cat. No. M5520S; NEBuilder Positive Control: New England 
Biolabs, Ipswich, MA, Cat. No. N2611A). Transformation was carried out using 
high efficiency competent 5α E. coli cells (New England Biolabs, Ipswich, MA, 
Cat. No. C2987H; SOC Medium: New England Biolabs, Ipswich, MA, Cat. No. 
B9020S; pUC 19 Control DNA: New England Biolabs, Ipswich, MA, N3041A).   
pWH013 (huAIRAP; AcGFP)
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Figure 3. Plasmid pWH014 
 
 pWH015 (9782 bp): This was prepared by cutting pWH013 with NotI enzyme 
(New England Biolabs, Ipswich, MA, Cat. No. R3189S). The product of 7931 bp 
was ligated with the PCR products of DsRed (template: pCL148 and primers: CL-
DsRed-F and CL-DsRed-R) of 703 bp and AIRAP (template: AIRAP. PolyA + 
CMV promoter and primers: CL-NotI-PolyA+CMV-KpnI-F and CL-NotI-
PolyA+CMV-KpnI-R) of 1201 bp using NEBuilder Assembly (HiFi DNA Master 
Mix: New England Biolabs, Ipswich, MA, Cat. No. M5520S; NEBuilder Positive 
Control: New England Biolabs, Ipswich, MA, Cat. No. N2611A). Similarly, 
transformation was carried out using high efficiency competent 5α E. coli cells 
pWH014 (huAIRAPL; AcGFP)
10189 bp
BclI - 464 - T'GATC_A - dam methylated!
AflIII - 735 - A'CryG_T
BstZ17I - 1317 - GTA'TAC
SpeI - 1470 - A'CTAG_T
AflII - 2208 - C'TTAA_G
EcoRV - 2294 - GAT'ATC
HindIII - 4067 - A'AGCT_T
SalI - 4084 - G'TCGA_C
AgeI - 4111 - A'CCGG_T
AleI - 4298 - CACnn'nnGTG
ClaI - 5435 - AT'CG_AT - dam methylated!
PshAI - 5467 - GACnn'nnGTC
AsiSI - 5804 - GCG_AT'CGC
AjuI - 6121 - GAAnnnnnnnTTGGnnnnnn_nnnnn'
AjuI - 6153 - CCAAnnnnnnnTTCnnnnnnn_nnnnn'
ArsI - 6268 - CrAAnnnnnnGTCnnnnnnnn_nnnnn'
ArsI - 6300 - GACnnnnnnTTyGnnnnnn_nnnnn'
BstXI - 6679 - CCAn_nnnn'nTGG
AhdI - 7634 - GACnn_n'nnGTC
BsaI - 7695 - GGTCTCn'nnnn_
XmnI - 8233 - GAAnn'nnTTC
PspXI - 8626 - vC'TCGA_Gb
BarI - 9460 - GAAGnnnnnnTACnnnnnnn_nnnnn'
BarI - 9492 - GTAnnnnnnCTTCnnnnnnn_nnnnn'
Z
F
A
N
D
2
B
C
M
V
P
o
ly
-A
C
M
V
AcG
FP
1
Poly-ASV40
H
ygromycin R
P
o
ly-A
SV40
Kan R/Neo R
P
ol
y-
A
A
m
p
 R
p
U
C
10 
 
(New England Biolabs, Ipswich, MA, Cat. No. C2987H; SOC Medium: New 
England Biolabs, Ipswich, MA, Cat. No. B9020S; pUC 19 Control DNA: New 
England Biolabs, Ipswich, MA, N3041A). 
Figure 4. Plasmid pWH015 
 
 pWH016 (10118 bp): The plasmid was constructed using pWH014 that was cut 
by SpeI enzyme (New England Biolabs, Ipswich, MA, Cat. No. R3133S) + 
HindIII enzyme (New England Biolabs, Ipswich, MA, Cat. No. R3104S)  and 
pWH015 was cut with SpeI enzyme (New England Biolabs, Ipswich, MA, Cat. 
No. R3133S) + HindIII enzyme (New England Biolabs, Ipswich, MA, Cat. No. 
R3104S). The 2597 bp fragment containing the AIRAPL gene from pWH014 was 
ligated with the 7521 bp fragment of pWH015 that had DsRed in it. The ligation 
pWH015 (huAIRAP; DsRed)
9782 bp
SpeI - 1470 - A'CTAG_T
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was carried out using DNA Quick Ligase enzyme (New England Biolabs, 
Ipswich, MA, Cat. No. M2200S). Furthermore, transformation was performed 
using high efficiency competent 5α E. coli cells (New England Biolabs, Ipswich, 
MA, Cat. No. C2987H; SOC Medium: New England Biolabs, Ipswich, MA, Cat. 
No. B9020S; pUC 19 Control DNA: New England Biolabs, Ipswich, MA, 
N3041A). 
.Figure 5. Plasmid pWH016 
 
 pWH017 (12272 bp): This was prepared by using pWH004-25 (containing 
human Amyloid Precursor Protein wild-type variant 3) that was cut with SapI 
enzyme (New England Biolabs, Ipswich, MA, Cat. No. R0569S). The product of 
6773 bp was ligated with the PCR products of Tet3G (template: pCMV-tet3G and 
pWH016 (huAIRAPL; DsRed)
10118 bp
SpeI - 8671 - A'CTAG_T
KpnI - 9505 - G_GTAC'C
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primers: CL-TetOn3G-F and CL-TetOn3G-R) of 2118 bp and Puromycin 
(template: pLVX-EF1a-IResPuro and primers: CL-Puromycin-F and CL-
Puromycin-R) of 3431 bp using NEBuilder Assembly (HiFi DNA Master Mix: 
New England Biolabs, Ipswich, MA, Cat. No. M5520S; NEBuilder Positive 
Control: New England Biolabs, Ipswich, MA, Cat. No. N2611A). Transformation 
was performed by using high efficiency competent 5α E. coli cells (New England 
Biolabs, Ipswich, MA, Cat. No. C2987H; SOC Medium: New England Biolabs, 
Ipswich, MA, Cat. No. B9020S; pUC 19 Control DNA: New England Biolabs, 
Ipswich, MA, N3041A). 
Figure 6. Plasmid pWH017 
 
 
pWH017
12272 bp
PvuII - 1139 - CAG'CTG
BamHI - 1337 - G'GATC_C
SacI - 1600 - G_AGCT'C
SapI - 3074 - GCTCTTCn'nnn_
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 pWH018: The plasmid was prepared by cutting pWH004-M31 (presence of 
human Aβ G37L variant 3) with SapI enzyme (New England Biolabs, Ipswich, 
MA, Cat. No. R0569S). The product of 6773 bp was ligated with the PCR 
products of Tet3G (2118 bp) and Puromycin (3431 bp) with help of NEBuilder 
Assembly (HiFi DNA Master Mix: New England Biolabs, Ipswich, MA, Cat. No. 
M5520S; NEBuilder Positive Control: New England Biolabs, Ipswich, MA, Cat. 
No. N2611A). Transformation was carried out using high efficiency competent 5α 
E. coli cells (New England Biolabs, Ipswich, MA, Cat. No. C2987H; SOC 
Medium: New England Biolabs, Ipswich, MA, Cat. No. B9020S; pUC 19 Control 
DNA: New England Biolabs, Ipswich, MA, N3041A). 
 .pWH019: This plasmid was constructed by cutting pWH004-32 (human 
Amyloid Precursor Protein Swedish variant 3) with SapI enzyme (New England 
Biolabs, Ipswich, MA, Cat. No. R0569S). Product of 6773 bp was ligated with the 
PCR products of Tet3G (2118 bp) and Puromycin (3431 bp) using NEBuilder 
Assembly (HiFi DNA Master Mix: New England Biolabs, Ipswich, MA, Cat. No. 
M5520S; NEBuilder Positive Control: New England Biolabs, Ipswich, MA, Cat. 
No. N2611A). For transformation, high efficiency competent 5α E. coli cells 
(New England Biolabs, Ipswich, MA, Cat. No. C2987H; SOC Medium: New 
England Biolabs, Ipswich, MA, Cat. No. B9020S; pUC 19 Control DNA: New 
England Biolabs, Ipswich, MA, N3041A) were used.  
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 pWH020 (8163 bp): This was prepared by using pWH013, cut with SacI enzyme 
(New England Biolabs, Ipswich, MA, Cat. No. R3156S) to remove the AIRAP 
gene. The larger fragment (containing AcGFP) was ligated using DNA Quick 
Ligase enzyme (New England Biolabs, Ipswich, MA, Cat. No. M2200S). The 
plasmid was used as a negative control. Consequently, transformation was carried 
out using high efficiency competent 5α E. coli cells (New England Biolabs, 
Ipswich, MA, Cat. No. C2987H; SOC Medium: New England Biolabs, Ipswich, 
MA, Cat. No. B9020S; pUC 19 Control DNA: New England Biolabs, Ipswich, 
MA, N3041A) were used.  
Figure 7. Plasmid pWH020 
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 pWH021 (8092 bp): Another negative control plasmid that was constructed by 
cutting pWH015 using SacI enzyme (New England Biolabs, Ipswich, MA, Cat. 
No. R3156S). DsRed gene was present in the larger fragment and the two ends 
were ligated using DNA Quick Ligase enzyme (New England Biolabs, Ipswich, 
MA, Cat. No. M2200S). Finally, transformation was performed using high 
efficiency competent 5α E. coli cells (New England Biolabs, Ipswich, MA, Cat. 
No. C2987H; SOC Medium: New England Biolabs, Ipswich, MA, Cat. No. 
B9020S; pUC 19 Control DNA: New England Biolabs, Ipswich, MA, N3041A). 
 
Figure 8. Plasmid pWH021 
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Plasmid DNA extraction 
Transformation gave rise to bacterial colonies, those were picked and grown overnight in 
presence of LB media (DifcoTM LB AGAR, MILLER, Becton Dickson and Company, Sparks, 
MD, Cat. No. 244520) containing Ampicillin (ThermoFisher Scientific, Waltham, MA, Cat. No. 
11593027). 1 ml of 100 mg/ml Ampicillin was added to 1 L of LB media (40 g of LB AGAR 
powder was dissolved in Milli-Q water to make up the total volume up to 1 L).  Finally, plasmid 
DNA was extracted using Monarch Plasmid Miniprep kit (New England Biolabs, Ipswich, MA, 
Cat. No. T1010S) following the manufacturer’s instructions.  
HT22 cells 
The hippocampus is a vital component of the brains of humans and other mammals that plays 
essential roles in long-term memory and spatial navigation. The hippocampus is one of the first 
regions of the brain to get affected by AD, along with problems related to memory and 
disorientation (18). HT22 cells, an immortalized mouse hippocampal cell line, have been widely 
used as in vitro model for studying the mechanism of oxidative stress-induced neuronal cell 
death (19). Additionally, it is known that glutamate is the main endogenous excitatory 
neurotransmitter in the central nervous system. But, high concentrations of this neurotransmitter 
are associated with neurotoxicity and might be involved in various neurodegenerative disorders, 
such as Alzheimer’s and Parkinson’s disease (20). Mechanisms of glutamate toxicity involve 
enhanced production of reactive oxygen species (ROS). In HT22 cells, elevated ROS levels 
result in lipid peroxidation, protein oxidation, DNA damage, and ultimately cell death (20). 
Thus, HT22 cell line has been mainly used to study glutamate-induced nonreceptor-mediated 
neurotoxicity (20).   
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Transfection 
HT22 mouse hippocampal cells were seeded 24 hours prior to transfection in a 48-well plate. 
Transfection was carried out the following day with help of chemical method. 1.5 μl of 
LipofectamineTM 3000 reagent (INVITROGEN, Carlsbad, CA, Cat. No. L3000001) was diluted 
with 25 μl of OPTI-MEMTM medium (Gibco, Life Technologies, Gaithersburg, MD, Cat. No. 
31985062) in one of the microcentrifuge tubes. 1 μg of plasmid DNA was diluted in 50 μl of 
OPTI-MEMTM medium, then 2 μl of P3000TM reagent (INVITROGEN, Carlsbad, CA, Cat. No. 
L3000001) was added and mixed thoroughly. This mixture was then added to the diluted 
LipofectamineTM 3000 reagent after which it was incubated for 10-15 minutes. Finally, DNA-
lipid complex was added to the neuronal cells. This was being performed by a lab mate. The 
transfected cells were analyzed after 48 hours.      
 
Cell lines 
We grew and maintained the following cell lines in order to test our overall goal.   
 WH1: HT22; pTRE3G_ Zs Green + pCMV_ Tet3G (transactivator) 
 WH2: HT22; pWH003 (pTRE3G_ Zs Green + Aβ) + pCMV_ Tet3G 
 WH3: HT22; pWH017 
 WH4: HT22; pWH018 
 WH5: HT22; pWH019 
 WH6: HT22; pWH013 
 WH7: HT22; pWH014 
 WH8: HT22; pWH015 
18 
 
 WH9: HT22; pWH016 
 WH10: HT22; WH1 + pWH021 
 WH11: HT22; WH1 + pWH015 
 WH12: HT22; WH1 + pWH016 
 WH13: HT22; WH2 + pWH021 
 WH14: HT22; WH2 + pWH015 
 WH15: HT22; WH2 + pWH016 
 WH16: HT22; pWH020 
 WH17: HT22; pWH021 
 WH18: HT22; pWH020 + pWH021 
 
Culture of cell lines 
Cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, CORNING, Corning, NY, 
Cat. No. 10-013-CV) with 10% fetal bovine serum (FBS, Sigma, St. Louis, MO, Cat. No. 
F6178), 1% penicillin/streptomycin (P/S, ThermoFisher Scientific, Waltham, MA, Cat. No. 
15140122), and 0.1% gentamycin (Lonza, Walkersville, MD, Cat. No. 17-518Z). All cells were 
incubated at 370C in 5% CO2 for propagation. Cell lines took time to grow, and this was 
dependent on the particular cell line. When the cells reached an appropriate number, the growth 
medium was aspirated off. We added 1 ml of trypsin (CORNING, Corning, NY, Cat. No. 25-
053-C1) to the cells in a T-25 flask and incubated at 370C for three minutes. This helped the 
attached cells to come off the bottom of the flask. 1 ml of DMEM was added to the cells already 
incubated with trypsin. Next, the cells were centrifuged at 500 x g for five minutes. The 
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supernatant was aspirated off the cell pellet and discarded. The cell pellet was resuspended in a 
volume of DMEM, vortexed so that the cells mixed uniformly in the growth medium.      
 
Growth rate and Confluence (%) of HT22 and HCN-2 
HT22 mouse hippocampal cells (14th passage) and HCN-2 human cortical cells (6th passage) 
were grown in 96-well plate. The cells were treated with 20 μl trypsin (CORNING, Corning, 
NY, Cat. No. 25-053-C1), and were allowed to come off the bottom of the plate. It was then 
resuspended in 20 μl DMEM (CORNING, Corning, NY, Cat. No. 10-013-CV), mixed 
thoroughly by vortexing, and the total number was assessed using a hemacytometer (Hausser 
Scientific, VWR, Radnor, PA, Cat. No. 23649-061). From the total cell count, growth rate and % 
confluence was studied for both cell types. 100% confluence was estimated if the number of cells 
reached 40,000 in one of the wells of a 96-well plate. Initially, 2000 cells each of HT22 and 
HCN-2 were seeded in the 96-well plate. After every 24 hours for 9 days, the cells were counted 
for growth rate and confluence (%).  
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where ‘n’ denotes the number of days.  
 
Cell viability assays 
Neurobasal medium (Gibco, Invitrogen, Carlsbad, CA, Cat. No. 21103049) was added to WH1 
and WH2 cell lines that were differentiated after 48 hours. In 100 ml Neurobasal medium, 1 ml 
N-2 Supplement (100X) and 2 mM L-glutamine was aseptically added. Next, the differentiated 
cells were seeded in a 48-well plate. Two repeats each of WH1 subclone (WH1 2 and WH1 3) 
20 
 
and WH2 subclone (WH2 1 and WH2 2) were considered for this assay. Doxycycline (1:1000 
dilution in DMEM) was added eventually and the cells were kept in the CO2 incubator for 72  
hours. This step helped to induce the production of green fluorescent protein (GFP) in WH1 and 
WH2 cells and amyloid-beta protein (Aβ) in WH2 cells. Cell viability assay was performed 
using Annexin V-Cy3 Apoptosis kit (BioVision, Milpitas, CA, Cat. No. K102-25). The DMEM 
was aspirated off and the cells were resuspended in 250 µl of 1X Annexin Binding Buffer. 2.5 µl 
of Annexin V-Cy3 was added and incubated for 10 minutes in dark. Finally, the cells were 
observed under a fluorescent microscope using a rhodamine filter. The apoptotic cells gave faint 
red color, while the dead ones were bright red. On the other hand, the live cells did not fluoresce 
at all.   
 
Next, cell lines WH8, WH9, and HT22 (control) were differentiated using neurobasal medium. 
The cells were eventually seeded (~ 125000) in a 6-well plate. 20 µM Aβ1-42 was added from      
1 mM Aβ1-42 stock to the three wells containing WH8, WH9, and HT22. The other three wells of 
the plate had only DMEM without Aβ. The cells were kept in the CO2 incubator for 48 hours. 
After the incubation period, cell viability was performed using 0.4% Trypan Blue Solution 
(Amresco, Solon, OH, Cat. No. K940). The cells were trypsinized and resuspended in 1 ml 
DMEM after which they were centrifuged at 500 x g for five minutes. The supernatant was 
aspirated off and the cell pellet was dissolved and mixed thoroughly in 180 μl of phosphate 
buffer saline (PBS, HyClone, Logan, UT, Cat. No. SH30256.01). Finally, 20 μl of 0.4% Trypan 
Blue Solution (1:10 volume of PBS) was added to the cells. The cells were incubated for 10 
minutes after which they were counted using a hemacytometer. The dead cells were stained blue 
by the stain, while the live cells were clear and translucent.    
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Differentiated HT22 cells were seeded (~ 40000) in a 48-well plate. Following day, the cells 
were transfected chemically with AIRAP DsiRNA (Integrated DNA Technologies, IDT, 
Coralville, IA, Cat. No. N001159908.1, N133349.12.3, and N133349.12.1) and AIRAPL 
DsiRNA (IDT, Coralville, IA, Cat. No. N001159905.1, N026846.12.12, and N001159906.1) 
along with negative control (NC-1, IDT, Coralville, IA, Cat. No. 51-01-14-04). 2.1 µl each of 
AIRAP DsiRNA, AIRAPL DsiRNA, and NC-1 from 50 µM stocks were added to the cells. After 
24 hours, the transfected cells were transferred from 48-well plate to 6-well plate. Finally, 20 µM 
Aβ1-42 was added from 1 mM Aβ1-42 stock to three wells containing HT22/AIRAP DsiRNA, 
HT22/AIRAPL DsiRNA, and HT22/NC-1. The other three wells containing the same set of cells 
did not have Aβ in them. The cells were incubated for 48 hours, after which they were stained 
using 0.4% Trypan Blue Solution and the cells were counted using a hemacytometer, following 
the same protocol that was used with cells lines WH8 and WH9.     
 
RNA isolation 
Doxycycline was added to WH1 (subclones 2 and 3), WH2 (subclones 1 and 2), HT22 cells and 
were seeded in a 6-well plate. WH1 and WH2 cells were harvested after 4, 8, 12, and 16-hour 
interval and HT22 cells were harvested after 0, 4, 8, 12, and 16-hour interval in 500 μl TRI 
Reagent Solution (RNA isolation reagent, Invitrogen, Thermo Fisher Scientific, Carlsbad, CA, 
Cat. No. AM9738). 50 μl of 1-Bromo-3-Chloropropane (Sigma-Aldrich, St. Louis, MO, Cat. No. 
B9673) was added to the samples in microcentrifuge tubes. The tubes were shaken vigorously 
for 30 seconds after which they were incubated for 3 minutes at room temperature. Next, the 
samples were centrifuged at 12000 x g for 15 minutes. The supernatant was transferred to 
another set of tubes that already had 250 μl of 2-Propanol (Sigma-Aldrich, St. Louis, MO, Cat. 
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No. I9516). The tubes were thoroughly vortexed after which the samples were incubated for 10 
minutes at room temperature. Eventually, samples were centrifuged at 12000 x g for 10 minutes. 
The supernatant was aspirated off and the pellet was washed with 500 μl of 75% ethanol. 
Samples were again centrifuged at 7500 x g for 5 minutes. The pellet was let to dry and finally it 
was dissolved in 50 μl of RNase free water. The samples were incubated at 550C water bath for 
10 minutes before further analysis.   
 
cDNA synthesis and Real-Time PCR 
The RNA samples were next used to make copies of complementary DNA (cDNA) using the 
manufacturer’s instructions (Takara, Mountain View, CA, Cat. No. RR037A). The cDNA 
samples were used to test the expression of AIRAP and AIRAPL using mouse AIRAP 
(PrimeTime qPCR Primers, IDT, Coralville, IA, Cat. No. 127013791) and AIRAPL (qPCR-
AIRAPL-Ms-F, qPCR-AIRAPL-Ms-R, IDT, Coralville, IA, Cat. No. 114282272 and 
114282273) primers, besides using the housekeeping primers, PGK1 (qPCR-PGK1-Ms-F, 
qPCR-PGK1-Ms-R, IDT, Coralville, IA, Cat. No. 114282325 and 114282324) and RPS18 
(qPCR-RPS18-Ms-F, qPCR-RPS18-Ms-R, IDT, Coralville, IA, Cat. No. 114282323 and 
114282322). We used SYBR Select Master Mix dye (Applied Biosystems, Life Technologies, 
Austin, TX, Cat. No. 4472897) to perform real-time PCR (StepOnePlus, Applied Biosystems, 
Waltham, MA, Cat. No. 4376300) and study the expression levels of AIRAP and AIRAPL.     
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Statistical Analysis 
Two-sample student t-test assuming unequal variances was performed to test if significant results 
were obtained in the experiments. Differences between experimental groups were considered 
statistically significant if the P-value was ≤ 0.05.     
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RESULTS 
 
Characterization of HT22 and HCN-2 cells 
 To characterize HT22 (14th passage) and HCN-2 (6th passage) cells, the cell number, growth 
rate, and confluence (%) were recorded for nine days at 24-hour intervals. As shown in Figure 
9A and 9B, starting with 2000 cells at day “0”, both cell types continued to grow until the 9th 
day, although the rate of proliferation decreased at day “6” (HT22) and day “7” (HCN-2).  
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Figure 9. Characterization of HT22 and HCN-2 cells. Both HT22 (A) and HCN-2 (B) were 
seeded at 2,000 cells/well in 96-well plate. All cells were incubated overnight and counted after 
every 24 hours, right after they were seeded. Cells were collected by trypsinization, and total 
cells were counted using a hemacytometer.  
 
Next, as shown in Figure 10A and 10B, the growth rate of HT22 and HCN-2 cells were 
calculated from the total cell number for nine days. It was observed that the growth rate of HT22 
was decreased after day “5”. This could be primarily due to the increase in number of cells with 
time in the 96-well plate. This showed that the cells started dividing and after a certain point 
when they were many as compared to the area of the 96-well plate, they stopped dividing. The 
growth rate of HCN-2 was analyzed and found that after day “6”, the cells started to divide 
slowly and hence their growth rate was lowered as compared to the days in the beginning.  
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Figure 10. Growth rate of HT22 and HCN-2 cells. Growth rate was calculated for nine days 
from the total cell count. For HT22 (A), it was similar right from the beginning, but after day 
“5”, it decreased till the last day. In case of HCN-2 (B), the growth rate was reduced after day 
“6”.   
 
 
As shown in Figure 11A and 11B, the confluence (%) of HT22 and HCN-2 cells were calculated 
from the total cell count. This was done in order to see the effect of confluence on cell growth.  
 It is estimated that if the total cell count was 40,000 in one of the wells of the 96-well plate, the 
confluence would be 100%. Based on that, the confluence was calculated for both HT22 and 
HCN-2 cells for nine days. On day “0”, both HT22 and HCN-2 cells had 5% confluence as 2000 
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cells were seeded on that day. The confluence reached 65.81% on day “3” and went up to 
135.5% on day “4”, for HT22 cells, since the number of cells were 54,200. The confluence was 
found to be 397.5% on day “9”, since the total number of cells were 159,000. Similarly, the 
confluence of HCN-2 was 100.08% on day “5”, as number of cells were 40,033. On day “9”, the 
confluence was found to be 385.12%, the number of cells being at 154,048. The confluence had 
a direct effect on the growth rate, for HT22, it went from 235.75% to 276.25% from day “5” to 
day “6”. Also, for HCN-2, the confluence was 175.12% on day “6”, and 222.50% on day “7”. 
This showed that the confluence did not increase in the same way as on the initial days after 
seeding in both cell types. As a result, the growth rate was lowered after day “5” in HT22 and 
after day “6” in HCN-2 cells.    
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Figure 11. Confluence (%) of HT22 and HCN-2 cells. Confluence was calculated for nine 
days based on: 40,000 cells/well = 100% confluence. There was an increase in the confluence of 
both HT22 and HCN-2 cells, each day, through nine days. But, the increase in confluence was 
lowered after day “5” in HT22 (A), and day “6” in HCN-2 (B), that in turn affected the growth 
rate in both cell types.   
 
 
Toxicity of Aβ on the neuronal cells 
WH1 (control) and WH2 cell lines were used for cell viability assay using Annexin V-Cy3 
Apoptosis kit. We used doxycycline-inducible system to trigger the production of Aβ. 
Doxycycline was added to both cell lines that were differentiated and incubated for 3 days. The 
apoptotic cells were stained red by the stain and cell viability (%) was calculated based on the 
number of dead cells present.  
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Table 1: % dead of differentiated WH1 and WH2 subclones with 72-hour Doxycycline 
treatment.  
Name of subclones Total Cells Dead Cells % Dead 
WH1 2 308 1 0.32 
WH1 3 432 2 0.46 
WH2 1 229 6 2.62 
WH2 2 282 7 2.48 
 
 
The WH2 cells were sicker (most likely due to the presence of Aβ) than the WH1 cell lines, as 
evident under the microscope. Some of them died after the incubation period in presence of 
doxycycline, and so, we calculated the number of viable cells present. However, most of the 
WH2 cells did not die, but were sicker and had undergone apoptosis as compared to the WH1 
subclones, which was evident from the calculated higher % dead after staining. The apoptotic 
and dead cells fluoresced red, while the live cells had no fluorescence.   
 
AIRAP/AIRAPL protection against Aβ toxicity 
Cell lines WH8, WH9, and HT22 (control) were used to study the protection of AIRAP/AIRAPL 
against Aβ. Aβ was added extracellularly and the differentiated cells were stained with Trypan 
Blue Solution after 2-day incubation. 
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Table 2: % dead cells in differentiated WH8, WH9, and HT22 after adding Aβ 
extracellularly and incubating for 2 days. Both WH8 and WH9 (6.40% and 6.57% 
respectively) had fewer dead cells compared to HT22 cells (8.04%).   
Name of Cell Lines Total Cells Dead Cells % Dead 
WH8 (without Aβ)  236 12 5.08 
WH8 + Aβ 125 8 6.40 
WH9 (without Aβ) 507 16 3.15 
WH9 + Aβ 350 23 6.57 
HT22 (without Aβ) 1700 148 8.70 
HT22 + Aβ 1193 96 8.04 
 
 
The percentage of dead cells was calculated in the presence and absence of Aβ. % dead in WH8 
and WH9 in presence of Aβ was found to be 6.40 and 6.57 respectively. Additionally, % dead in 
HT22 cells (control) in presence of Aβ was 8.04. This data  is consistent with  protection offered 
by AIRAP (WH8) and AIRAPL (WH9), since both cell lines had lower numbers of dead cells 
than the HT22 cells. However, the number of HT22 cells were way higher than both WH8 and 
WH9 during the time of counting. Moreover, HT22 cells without Aβ had higher % dead than 
HT22 with Aβ, which was most likely due to experimental variations.. This and the lack of 
repeats make this experiment hard to interpret.. Future experiments, should include multiple 
repeats of each condition- preferably 4 or more- and a standardized cell number and density. The 
inclusion of HT22 expressing an irrelevant protein (e.g. GFP or DsRed) as an additional control 
would also be advisable.       
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Effect of AIRAP/AIRAPL knockdown on Aβ toxicity 
Differentiated HT22 cells were used to knockdown the expression of AIRAP and AIRAPL with 
help of specific DsiRNA. Negative control (NC) was used where AIRAP and AIRAPL 
expression was not targeted. . Aβ was added extracellularly and the cells were stained with 
Trypan Blue Solution after a 2-day incubation. 
Table 3: % dead cells when AIRAP and AIRAPL expression have been knocked down in 
presence of extracellular Aβ. The cells where AIRAP and AIRAPL expressions were knocked 
down had more dead cells (12.92% and 15.71% respectively) compared to the NC, where the 
expressions were restored.   
Name of Cell Lines Total Cells Dead Cells % Dead 
HT22/AIRAPi 
(without Aβ)  
1382 142 10.27 
HT22/AIRAPi + Aβ 1416 183 12.92 
HT22/AIRAPLi 
(without Aβ) 
1460 108 7.39 
HT22/AIRAPLi + Aβ 1012 159 15.71 
HT22/NC       
(without Aβ) 
2154 257 11.93 
HT22/NC + Aβ 1510 145 9.60 
  
 
The percentage of dead cells was calculated both in presence and absence of Aβ. Cells where 
AIRAP and AIRAPL expression were knocked  down and treated with Aβ (HT22/AIRAPi + Aβ 
and HT22/AIRAPLi + Aβ), had 12.92% and 15.71% dead cells respectively, whereas HT22/NC 
+ Aβ had 9.60% cells that were dead. This is consistent with  our hypothesis that knockdown of 
AIRAP/AIRAPL increases cell death, thus lowering the number of viable cells. However, there 
were higher numbers of dead cells in HT22/NC in absence of Aβ (11.93%) than in presence of 
Aβ (9.60%), although there were more number of cells in HT22/NC than in HT22/NC + Aβ, 
which could account for higher dead cells at the end of incubation period. It is not possible to 
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interpret this data in the absence of experimental repeats. Therefore, additional experiments are 
needed before a final conclusion can be made.      
 
Expression of AIRAP and AIRAPL in response to induced Aβ 
Real-time PCR was performed on WH1 (subclones 2 and 3) and WH2 (subclones 1 and 2) that 
were treated with doxycycline and harvested after 4, 8, 12, 16, 24, and 48-hour interval (T4-
T48). Both WH1 (denoted by “GFP”) and WH2 (denoted by “Aβ”) were treated in the absence 
of doxycycline and harvested right away after seeding (T0). It was observed that expression of 
AIRAP (Figure 12A) in WH2 cells was increased at 4 and 8-hour interval when compared to 
WH1 cells, although the increase was not statistically significant (P-value ≤ 0.7402). At 12-hour 
interval, the expression level was similar in both WH1 and WH2 cells with an increased AIRAP 
level in WH1 cells at the 16-hour interval. However, AIRAP expression was not enhanced in 
WH2 cells at 16-hour interval. By the end of 24 and 48-hour interval, it was observed that the 
expression dropped drastically in both WH1 and WH2 cells. Also, at T0, the expression was 
lowered in WH2 cells.    
As shown in Figure 12B, there was a steady increase in the expression of AIRAPL in WH2 cells 
as compared to WH1 cells at 0, 4, 8, and 12-hour interval, although the change was not 
statistically significant (P-value ≤ 0.5048). However, AIRAPL expression was reduced in WH2 
cells as compared to WH1 at 16, 24, and 48-hour interval.  
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Figure 12: Time-course experiment showing expression of AIRAP (A) and AIRAPL (B) in 
WH1 and WH2 cells at 0, 4, 8, 12, 16, 24, and 48-hour interval with doxycycline treatment. 
WH2 cells had enhanced AIRAP expression than WH1 at 4 and 8-hour interval while AIRAPL 
expression was enhanced at 0 till 12-hour interval in WH2. AIRAP expression was increased in 
WH1 cells at the 16-hour interval, while AIRAPL expression was enhanced in WH1 cells at 16, 
24, and 48-hour interval. The data was normalized to WH1 T0 for both AIRAP and AIRAPL.   
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Furthermore, we wanted to study AIRAP and AIRAPL expressions in absence of Aβ induction  
in WH1 (GFP) and WH2 (Aβ) cells to confirm that any changes in AIRAP and AIRAPL 
expression levels found after induction were due to the expression of the transgene, rather than 
inherent differences between the two cell lines. It was shown that there were no statistically 
significant differences in AIRAP and AIRAPL expression between uninduced WH2 and WH1 
cells. (Figures 13A and 13B).      
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Figure 13: AIRAP (A) and AIRAPL (B) expressions in WH1 and WH2 cells in absence of 
doxycycline. WH2 cells had moderate increase in expression of AIRAP and AIRAPL than WH1 
cells.   
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DISCUSSION 
 
In this study, we hypothesized that AIRAP and AIRAPL could have a protective effect on the 
toxicity related to Aβ in mouse hippocampal cells. We used cell lines, WH1 and WH2, to 
determine the toxicity of Aβ. We may have found higher percentage of apoptotic and dead cells 
in WH2 than in WH1 after inducing the production of Aβ in WH2 cells via doxycycline. 
Although, doxycycline helped to induce Aβ intracellularly in WH2, the cells were not 
completely abolished after 3-days incubation period. However, most of the cells went into 
apoptotic stage, which was evident from the red fluorescence of the cells when stained with 
Annexin V. The WH2 cells appeared sicker than WH1. The live or the healthy cells were not 
stained at all, this was more frequently seen in WH1 cells, since the cell line did not have Aβ in 
them. We also used WH1 and WH2 cells without adding doxycycline in order to prevent the 
production of Aβ. It was found that the viability of WH1 and WH2 cells were similar after the 
incubation period. This was due to inability of WH2 cells to produce Aβ in absence of 
doxycycline, thus the cells were healthier and more viable.  
 
Next, we wanted to study the effect of AIRAP and AIRAPL overexpression on Aβ toxicity. We 
used cell lines, WH8 and WH9, where AIRAP and AIRAPL were overexpressed using a CMV 
constitutive promoter. After treating the cells with Aβ1-42, it was found that there were fewer 
dead cells in WH8 and WH9 compared to the HT22 cells that were treated with Aβ1-42 as well. 
This conclusion is consistent with our hypothesis  that AIRAP/AIRAPL overexpression could 
have a protective effect on the Aβ toxicity. One major drawback related to this particular 
conclusion could be the presence of fewer cells in WH8 and WH9 as compared to the HT22 cells 
after the incubation period. This might be due to the different rate of growing of HT22 and 
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WH8/WH9 cells. Furthermore, it was also found that the cells treated with Aβ1-42 had lesser 
number of cells after the incubation period as compared to the cells without Aβ1-42, although, 
equal number of cells were seeded at the beginning of the experiment. This could be due to Aβ 
inhibiting the normal growth of cells. Moreover, it was found that there were higher number of 
dead cells in HT22 without Aβ than in HT22 with Aβ due to experimental variations, although, 
Aβ is known to be toxic to the hippocampal cells. Besides, we did not use more repeats of WH8, 
WH9, and HT22 with/without Aβ, which would have helped to get a conclusive result.    
 
Additionally, we wanted to study viability of cells after knocking down AIRAP/AIRAPL 
expression to confirm that AIRAP/AIRAPL were actually responsible for the protection against 
Aβ. We used HT22 cells and knocked down AIRAP and AIRAPL expression with help of 
specific DsiRNA. Eventually, the cells were treated with Aβ1-42 and stained using Trypan Blue 
Solution. Higher percentage of the number of dead cells appeared to be in cells where the 
expression of AIRAP/AIRAPL was knocked out (HT22/AIRAPi + Aβ and HT22/AIRAPLi + 
Aβ) as compared to cells having intact expression of both the genes. In other words, presence of 
AIRAP and AIRAPL contributed to higher number of viable cells that was shown in HT22/NC + 
Aβ. Hence, it was inferred that in absence of AIRAP and AIRAPL, the condition of the cells 
worsened and so we got more number of dead cells. However, we should have used more repeats 
of the cell lines in order to provide a more detailed explanation of the protection offered by 
AIRAP/AIRAPL against Aβ toxicity. Future studies should aim to consider more repeats of each 
condition (AIRAP/AIRAPL knockdown, cell lines having intact expression of AIRAP/AIRAPL, 
as well as presence/absence of Aβ) to make a final conclusion.    
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Finally, we studied the gene expression of AIRAP and AIRAPL in presence of GFP and Aβ that 
was induced with help of doxycycline. WH1 and WH2 cells were treated with doxycycline at 
different intervals such as 4, 8, 12, 16, 24, and 48-hour. It was found that WH2 cells had higher 
levels of both AIRAP and AIRAPL (although not statistically significant) during the initial 
stages of induction of Aβ (4 and 8 hour) as compared to WH1. For the 12-hour treatment, both 
WH1 and WH2 cells had similar levels of AIRAP, although, AIRAPL expression was enhanced 
but not significantly in WH2 than in WH1 at 12-hour induction with doxycycline. But, it was 
found that by the 16-hour treatment with doxycycline, levels of AIRAP and AIRAPL decreased 
in WH2 than in WH1 cells. This could be due to the reduction of the effect of Aβ production 
with increase in the treatment time, thus lowering the gene expression levels. We also studied the 
expression levels in absence of doxycycline. It was shown that   there were no statistically 
significant differences in AIRAP and AIRAPL expression levels in uninduced WH1 and WH2 
cells. However, the time-course experiment at T0 showed lower AIRAP expression in WH2 than 
in WH1. Hence, more studies are required to get conclusive evidences about the expressions of 
AIRAP and AIRAPL in response to Aβ induction.         
 
In the present study, we reported for the first time that AIRAP and AIRAPL could have 
protective effect against Aβ toxicity in mouse hippocampal cells. Through our findings and from 
other related studies, it is clear that Aβ is toxic to the mouse neuronal cells and the cells undergo 
apoptosis and eventually die in presence of Aβ. Cell lines that overexpress AIRAP/AIRAPL 
(WH8/WH9), appeared to offer protection against Aβ toxicity, thus helping in ameliorating the 
condition of the cells. Since, the experiment did not have more repeats, the findings could not be 
precise and definitive. Additionally, knockdown of both AIRAP/AIRAPL deteriorated the 
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condition of the cells, thus increasing the number of dead cells. Future studies should aim to 
consider more repeats of cell lines to get more conclusive results. Also, it would be interesting to 
study the effect of proteasome in the protection offered by AIRAP/AIRAPL against Aβ toxicity 
and thus could provide the potential mechanism for protection. Furthermore, we studied 
AIRAP/AIRAPL gene expression in cells having induced Aβ. It was noted that levels of 
AIRAP/AIRAPL were higher (not significant) at initial course of the experiment in cells having 
induced Aβ than in cells not having Aβ (having GFP alone). This finding suggested that 
AIRAP/AIRAPL was being produced in response to Aβ, which in turn helped to offer protection 
against the toxicity. However, with increase in the treatment time with doxycycline, the levels 
started to decline in response to Aβ. Finally, in future, it would be exciting to study the effect of 
AIRAP/AIRAPL in response to Aβ, added extracellularly to the HT22 cells.         
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